Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Human cytomegalovirus

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Human cytomegalovirus. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2014-002150-39 Sponsor Protocol Number: CCSJ148X2201 Start Date*: 2015-03-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled, study to evaluate the efficacy and safety of CSJ148 compared to placebo to prevent human cytomegalovirus (HCMV) replication in stem cel...
    Medical condition: human cytomegalovirus (HCMV) in stem cell transplant patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004862 10009703 CMV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022514-47 Sponsor Protocol Number: NV25409 Start Date*: 2011-09-05
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients
    Medical condition: Treatment and prevention of CMV disease in kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004862 10049107 CMV viraemia LLT
    16.0 100000004862 10009703 CMV infection LLT
    16.0 100000004848 10009701 CMV LLT
    16.0 100000004862 10060577 CMV viremia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Ongoing) ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-004445-17 Sponsor Protocol Number: hCMV2013 Start Date*: 2014-03-05
    Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE
    Full Title: A PROSPECTIVE RANDOMIZED STUDY FOR PREDICTING HUMAN CYTOMEGALOVIRUS (hCMV) INFECTION ACCORDING TO BASELINE hCMV-SPECIFIC T-CELL RESPONSE IN KIDNEY TRANSPLANT PATIENTS
    Medical condition: cytomegalovirus infection in renal tranplant recipients
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-004692-19 Sponsor Protocol Number: 963 Start Date*: 2007-12-19
    Sponsor Name:Biotest AG
    Full Title: Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study...
    Medical condition: Congenital CMV infection after primary CMV infection during pregnancy
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10010420 Congenital CMV infection LLT
    Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004233-86 Sponsor Protocol Number: V160-002 Start Date*: 2018-09-06
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: Double-Blind, Randomized, Placebo-Controlled Phase 2b, Multi-center Study to Evaluate the Safety, Tolerability, Efficacy and Immunogenicity of a 2-Dose and a 3- Dose Regimen of V160 (Cytomegaloviru...
    Medical condition: Cytomegalovirus infection (CMVi)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10009703 CMV infection LLT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: FI (Completed) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-000763-45 Sponsor Protocol Number: P-105-401 Start Date*: 2022-07-25
    Sponsor Name:AlloVir, Inc.
    Full Title: Global Registry for Long-Term Follow-up of Patients Participating in Clinical Trials with Posoleucel (ALVR105)
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Ongoing) SE (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001055-30 Sponsor Protocol Number: MK8228-002 Start Date*: 2018-04-09
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of MK-8228 (Letermovir) Versus Valganciclovir for the Prevention of Human Cytomegalovir...
    Medical condition: Prevention of CMV disease in D+/R- kidney transplant recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) AT (Completed) FR (Completed) HU (Completed) GB (GB - no longer in EU/EEA) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001326-25 Sponsor Protocol Number: MK-8228-030 Start Date*: 2019-05-27
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase 2b open-label, single-arm study to evaluate pharmacokinetics, efficacy, safety and tolerability of letermovir in pediatric participants from birth to less than 18 years of age at risk of de...
    Medical condition: Cytomegalovirus (CMV) infection in pediatric allogeneic HSCT recipients
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) Outside EU/EEA FR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005575-13 Sponsor Protocol Number: CMV12/12 Start Date*: 2013-05-16
    Sponsor Name:Antwerp University Hospital
    Full Title: Prophylactic vaccination with autologous dendritic cells against human cytomegalovirus: a pilot study in patients awaiting kidney transplantation
    Medical condition: Cytomegalovirus infection in patients awaiting kidney transplantation and after kidney transplantation
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004865 10046859 Vaccination LLT
    15.1 100000004857 10023418 Kidney failure LLT
    15.1 100000004862 10009703 CMV infection LLT
    15.1 100000004865 10023438 Kidney transplant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005105-27 Sponsor Protocol Number: P-105-202 Start Date*: 2022-05-02
    Sponsor Name:AlloVir, Inc.
    Full Title: Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of ALVR105 (Viralym-M) Compared to Placebo for the Prevention of AdV, BKV, CMV, EBV, HHV...
    Medical condition: Adenovirus (AdV), BK virus (BKV), John Cunningham virus (JCV), human herpesvirus 6 (HHV- 6), Epstein-Barr virus (EBV), and cytomegalovirus (CMV) infections and/or disease in patients at high risk f...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    20.1 10021881 - Infections and infestations 10055181 BK virus infection PT
    22.0 10021881 - Infections and infestations 10020431 Human herpesvirus 6 infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10023163 JC virus infection PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) FR (Completed) ES (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-006051-17 Sponsor Protocol Number: mRNA-1647-P301 Start Date*: Information not available in EudraCT
    Sponsor Name:ModernaTX, Inc.
    Full Title: A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Year...
    Medical condition: Prevention of Cytomegalovirus infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adolescents, Under 18, Adults Gender: Female
    Trial protocol: BE (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) EE (Trial now transitioned) FI (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-002047-15 Sponsor Protocol Number: CCSJ148X2202 Start Date*: 2018-08-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, patient, investigator and sponsor blinded, placebo-controlled phase II study to evaluate the efficacy and safety of CSJ148 in pregnant women with primary HCMV infection
    Medical condition: Congenital human cytomegalovirus (HCMV) infection in pregnant women
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10010420 Congenital CMV infection LLT
    Population Age: In utero, Newborns, Infants and toddlers, Under 18, Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000853-29 Sponsor Protocol Number: TRACE Start Date*: 2020-01-14
    Sponsor Name:Klinikum der Universität München
    Full Title: Treatment of chemo-refractory viral infections after allogeneic stem cell transplantation with multispecific T cells against CMV, EBV and AdV: A phase III, prospective, multicentre clinical trial
    Medical condition: Chemo-refactory AdV, CMV and EBV infections after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    22.0 10042613 - Surgical and medical procedures 10067859 Allogenic stem cell transplantation PT
    20.1 10021881 - Infections and infestations 10011831 Cytomegalovirus infection PT
    21.1 10021881 - Infections and infestations 10060931 Adenovirus infection PT
    21.1 10021881 - Infections and infestations 10015108 Epstein-Barr virus infection PT
    Population Age: Infants and toddlers, Children, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-003831-31 Sponsor Protocol Number: 8228-001 Start Date*: 2014-04-23
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
    Full Title: A Phase III Randomized, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-8228 (Letermovir) for the Prevention of Clinically Significant Human Cytomegalovirus (CMV) Infect...
    Medical condition: Clinically significant CMV infection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) LT (Completed) IT (Completed) FI (Completed) AT (Completed) ES (Completed) BE (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002069-77 Sponsor Protocol Number: RG101-05 Start Date*: 2016-12-01
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101
    Medical condition: Hepatitis C Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    19.0 10021881 - Infections and infestations 10019761 Hepatitis cytomegalovirus LLT
    19.0 100000004848 10057394 Hepatitis C positive LLT
    19.0 10021881 - Infections and infestations 10019760 Hepatitis CMV LLT
    19.0 10021881 - Infections and infestations 10047457 Viral hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006560-11 Sponsor Protocol Number: FARM7J4HCH Start Date*: 2009-02-24
    Sponsor Name:OSPEDALE POLICLINICO S. MATTEO
    Full Title: Prevention of human cytomegalovirus (HCMV) mother-to-fetus transmission by administration of virus-specific hyperimmune globulin to pregnant women with primary HCMV infection
    Medical condition: Pregnant women with primary HCMV infection.
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-000092-13 Sponsor Protocol Number: INF-001 Start Date*: 2011-05-16
    Sponsor Name:
    Full Title: A trial aimed at enhancing immunity to Influenza in elderly individuals through reversal of immune senescence mediated by herpes virus infection.
    Medical condition: The trial is aimed to improve the efficiency of the seasonal influenza vaccine. Healthy volunteers who are positive for cytomegalovirus (CMV) will be recruited and given anti-viral treatment. We h...
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004726-34 Sponsor Protocol Number: SHP620-302 Start Date*: 2017-09-01
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...
    Medical condition: Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10021819 Infection in marrow transplant recipients LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) BE (Completed) CZ (Completed) PL (Completed) FR (Completed) HR (Completed) IT (Completed) GR (Completed) AT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-005047-32 Sponsor Protocol Number: H-100-002 Start Date*: 2018-09-27
    Sponsor Name:Hookipa Biotech GmbH
    Full Title: A Randomized, Placebo-Controlled, Phase 2 Study of HB-101, a Bivalent Cytomegalovirus (CMV) Vaccine, in CMV-Seronegative Recipient (R-) Patients Awaiting Kidney Transplantation from Living CMV-Sero...
    Medical condition: Prevention of clinically significant cytomegalovirus (CMV) infection
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10072247 Cytomegalovirus immunisation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) BE (Completed) FR (Completed) AT (Completed) NO (Completed) DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002492-17 Sponsor Protocol Number: VISIT-V2 Start Date*: 2016-06-17
    Sponsor Name:St. Anna Kinderkrebsforschung
    Full Title: Treatment of adenovirus and cytomegalovirus infection post human allogeneic stem cell transplantation with short-term expanded virus-specific T cells
    Medical condition: Patients undergoing allogeneic HSCT undergo weekly screening for HAdV and CMV PCR. In case of viraemia ≥ 100 copies/ml PB preemptive antiviral with either Gancyclovir or Cidofovir conform to the ...
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004848 10050541 Cytomegalovirus antigen positive LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 09 00:57:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA